Coya Therapeutics, Inc. (NASDAQ: COYA)

Coya Therapeutics, Inc., a clinical-stage biotechnology company (NASDAQ: COYA), operates in the biotechnology industry, focusing on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). Tregs are crucial in suppressing inflammatory responses and maintaining self-tolerance in mammals. The company's primary use of cash is to fund operating expenses, consisting of research and development expenditures and general and administrative expenditures. Coya Therapeutics expects to continue incurring significant expenses and operating losses as it advances its product candidates through all stages of development and clinical trials, seeking regulatory approval.

Coya Therapeutics' main business activities revolve around three distinct potential therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. These modalities aim to address Treg dysfunction, identified as a significant pathophysiological component of neurodegenerative, autoimmune, and metabolic diseases.

The company generates revenue by developing therapies targeting Treg dysfunction. Coya Therapeutics' primary products include COYA 301, a biologic for subcutaneous administration that enhances Treg function and expands Treg numbers in vivo, and COYA 302, a biologic combination product candidate that suppresses inflammation via administration of a fusion protein (CTLA4-Ig) in conjunction with COYA 301.

Coya Therapeutics' competitive advantages stem from its understanding of Treg cell biology and the diseases where Treg cellular dysfunction is considered a likely driver of pathology. The company competes with various global pharmaceutical, biotechnology, specialty pharmaceutical, and generic drug companies that engage in drug development activities. Coya Therapeutics believes its product candidates will compete on the basis of efficacy, safety, convenience of administration and delivery, price, and the availability of reimbursement from government and other third-party payors.

Coya Therapeutics' customers include pharmaceutical companies, healthcare providers, and research institutions. In December 2023, the company entered into a Development and License Agreement with Dr. Reddy's Laboratories, Ltd. (DRL) for the exclusive, royalty-bearing right and license to commercialize COYA 302 solely for use in patients with amyotrophic lateral sclerosis (ALS) in the United States, Canada, the European Union, and the United Kingdom.

Key brand names and/or trade names of its products and services include COYA 301, COYA 302, COYA 201, COYA 206, and COYA 101. COYA 201 and COYA 206 are Treg-derived exosome product candidates, while COYA 101 is an autologous regulatory T cell therapy requiring no genetic manipulation. The company is also developing technology in conjunction with Carnegie Mellon University to target Treg exosomes to proteins of interest while loading with cargo of interest, requiring no genetic manipulation.